Ezra Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ezra Pharma, founded in 2018, is a US-based specialty pharmaceutical company operating in the generic and brand drug sectors. It differentiates itself through a suite of proprietary drug delivery technologies, which it uses to develop complex and innovatively formulated products. The company has filed several applications with the FDA and maintains a portfolio of investigational candidates, positioning it in the competitive landscape of advanced generic and specialty pharmaceuticals. Its mission centers on enhancing therapy quality and accessibility through technological innovation in formulation.

Generic Drugs

Technology Platform

Proprietary drug delivery technologies for innovatively formulated generic and brand drug products.

Opportunities

The company targets the high-value complex generic and 505(b)(2) drug markets, which offer higher barriers to entry and better profitability than simple generics.

Growing demand for improved drug delivery and accessible specialty therapies creates a favorable market tailwind.

Risk Factors

Key risks include regulatory hurdles in FDA approvals for complex products, intense competition from larger generic and specialty pharma firms, and reliance on external funding as a private, pre-commercial entity.

Competitive Landscape

Ezra competes in the specialty and complex generic pharmaceutical sector against large generic manufacturers (e.g., Teva, Viatris) and specialized drug delivery companies. Its differentiation relies on its proprietary formulation technologies to create improved or hard-to-copy products.

More companies in Small Molecule Drugs →More companies in United States →